This Plain Language Summary of publication article (PLSP) from Future Oncology outlines the CAPItello-291 study, which investigated the effectiveness of capivasertib combined with fulvestrant in patients with advanced HR-positive, HER2-negative breast cancer that could not be surgically removed. Participants had previously been treated with aromatase inhibitors but saw cancer progression. Researchers aimed to determine if this medication combination was more effective than a placebo with fulvestrant. Capivasertib works by inhibiting the AKT protein within cancer cells.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.